- UroToday Home
- Urologic Oncology
The Latest Bladder Cancer Research
Recent Abstracts
-
A Panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.Bladder CancerMarch 4, 2021
-
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.Bladder CancerMarch 4, 2021
-
Race as a predictor of pathologic response to neoadjuvant chemotherapy at time of cystectomy for bladder cancer.Bladder CancerMarch 4, 2021
-
Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma.Bladder CancerMarch 3, 2021
-
Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer.Bladder CancerMarch 3, 2021
-
The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.Bladder CancerMarch 3, 2021
-
Primary Complete Transurethral Resection of Bladder Tumor using Photodynamic Diagnosis for High-risk Non-Muscle Invasive Bladder Cancer: Is a Restaging Photodynamic Transurethral Resection Really Necessary?Bladder CancerMarch 2, 2021
-
Complete Metabolic Response with FDG-PET-CT Predicts Survival after Induction Chemotherapy in patients with Clinically Node-positive Bladder Cancer.Bladder CancerMarch 2, 2021
-
Oncologic equipoise between robotic and open radical cystectomy.Bladder CancerMarch 2, 2021
-
Influence of nutritional status and frailty phenotype on health-related quality of life of patients with bladder or kidney cancer.Bladder CancerMarch 1, 2021
Beyond the Abstracts
-
Midterm Follow-up (3 Years) Confirms and Extends Short-Term Results of Intravesical Gemcitabine as Bladder-Preserving Treatment for Non-Muscle-Invasive Bladder Cancer After BCG Failure - Beyond the AbstractBladder CancerFebruary 24, 2021
-
Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer - Beyond the AbstractBladder CancerFebruary 9, 2021
-
Bladder Tumor Subtype Commitment Occurs in Carcinoma In-Situ Driven by Key Signaling Pathways Including ECM Remodeling - Beyond the AbstractBladder CancerFebruary 3, 2021
-
Validation of the Khorana Score for Prediction of Venous Thromboembolism After Robot-Assisted Radical Cystectomy - Beyond the AbstractBladder CancerJanuary 27, 2021
-
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy - Beyond the AbstractBladder CancerJanuary 25, 2021
-
[18F]Fluoro-Deoxy-Glucose Positron Emission Tomography to Evaluate Lymph Node Involvement in Patients with Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Pembrolizumab - Beyond the AbstractBladder CancerJanuary 22, 2021
-
Can Anesthetics Affect Bladder Cancer Recurrence? Total Intravenous Versus Volatile Anesthesia in Patients Undergoing Robot-Assisted Radical Cystectomy: A Single Institution Retrospective Analysis - Beyond the AbstractBladder CancerJanuary 22, 2021
-
Can Immune Markers Help Identify Fast Relapse in Patients With Muscle Invasive Bladder Cancer? - Beyond the AbstractBladder CancerJanuary 21, 2021
-
Intracorporeal Versus Extracorporeal Urinary Diversion Following Robot-Assisted Radical Cystectomy: A Meta-Analysis, Cumulative Analysis, and Systematic Review - Beyond the AbstractBladder CancerJanuary 15, 2021
-
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program - Beyond the AbstractBladder CancerJanuary 14, 2021